Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.05M-45.4%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$223K-67.9%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$1.7M+0.6%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$418K+186%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.96B+1,120%
Enterprise value$5.91B+1,289%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net loss$(31,820)$(20,999)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense6,9684,883
Net accretion of premiums and discounts on marketable securities(446)(1,797)
Non-cash lease expense14362
Depreciation expense4316
Changes in operating assets and liabilities:
Prepaid expenses and other current assets461(148)

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Oruka Therapeutics, Inc. (ORKA) reported accretion (amortization) of discounts and premiums, investments of $446K in Q1 2026.
How has Oruka Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Oruka Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 75.2% year-over-year, from $1.8M to $446K.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the non-cash adjustment to the carrying value of investment securities due to the amortization of premiums or accretion of discounts over the life of the instrument. It reconciles the difference between the purchase price and the face value of debt securities held as investments. This adjustment is necessary to reflect the effective interest income earned on the investment portfolio.

Ask your AI about Oruka Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude